Gyre Therapeutics, Inc.

NASDAQ:GYRE

Biotechnology

Healthcare
$4.34 -0.15%

+$0.00 today

Market cap
$475.02M
Beta
4.92
P/E (TTM)
-88.3
EPS (TTM)
-$0.07
52W Low $5.44High $9.42

Volume 0.47M

Average 0.09M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

$1.01M

FY 2025 · Annual

Investing Cash Flow

-$474,000.00

FY 2025 · Annual

Financing Cash Flow

$24.38M

FY 2025 · Annual

+1059.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(87.93M)4.31M(85.48M)17.9M9.88M
Depreciation & Amortization290K1.13M1.11M1.59M2.48M
Deferred Income Tax(3.89M)(838K)(1.16M)(1M)(1.11M)
Stock-Based Compensation3.41M13.37M7.28M831K7.16M
Change in Working Capital483K(7.8M)7.46M(15.69M)(15.55M)
Accounts Receivables1.5M(7.92M)1.3M(9.29M)(11.95M)
Inventory3.88M(879K)1.75M(2.14M)(3.63M)
Accounts Payables500K(112K)192K(245K)13K
Other Working Capital(5.39M)1.11M4.22M(4.02M)17K
Other Non-Cash Items3.89M503K96.68M(7.27M)(1.85M)
Operating Cash Flow(83.76M)10.68M25.89M(3.64M)1.01M
Capital Expenditures(839K)(5M)(8.59M)(3.13M)(1.19M)
Acquisitions (Net)0(1.33M)4.02M(1.69M)30K
Purchases of Investments0(7.48M)(15.74M)(15.47M)0
Sales of Investments49.03M0000
Other Investing Activities0(13K)471K(412K)686K
Investing Cash Flow48.19M(13.81M)(19.76M)(19.88M)(474K)
Debt Repayment(6.7M)0000
Common Stock Issued49.55M00773K25.87M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities6.7M001.33M(1.49M)
Financing Cash Flow49.55M02.5M2.1M24.38M
Effect of Forex Changes0(1.89M)(298K)(273K)343K
Net Change in Cash13.99M(5.03M)8.33M(21.7M)25.26M
Free Cash Flow(84.59M)5.68M17.31M(6.77M)(180K)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income$9.9M
+ D&A$2.5M
+ Stock-Based Comp$7.2M
- Deferred Tax-$1.1M
- Working Capital-$15.6M
- Other Non-Cash-$1.8M
= Operating Cash Flow$1.0M
- Capex-$1.2M
= Free Cash Flow-$180.0K

Analysis

FY2025 free cash flow is -$180.0K. FCF conversion is -1.8% of net income. Operating cash flow was $1.0M, with capex of -$1.2M. The largest bridge item is Working Capital at -$15.6M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 6, 2026
8-KCurrent reportNov 5, 2026
8-KCurrent reportOct 22, 2026
8-KCurrent reportSep 1, 2026
S-8S-8 filingAug 27, 2026

Does GYRE generate free cash flow?

Gyre Therapeutics, Inc. (GYRE) generated -$180,000.00 of free cash flow in fiscal 2025.

How much operating cash flow does GYRE produce?

Operating cash flow was $1.01M, before capital expenditures of $1.19M.